The EgA1 anti-EGFR nanobody was used for constructing LiTE (light T-cell engager) and ATTACK (asymmetric tandem trimerbody for T-cell activation and killing cancer) bispecific engagers by combining one and three EGFR-binding nanobodies with a single CD3-binding scFv, respectively. The gene discussed is EGFR; the disease is cancer.